Kevin Sheth, MD, Co-Founder & Chief Medical Officer, Alva Health

Dr. Kevin Sheth is the (part time) Chief Medical Officer and Co-Founder of Alva Health has led clinical trials for the FDA clearance and clinical validation of medical devices and therapeutics in the field of stroke. After completing training in neurology and a fellowship in vascular neurology and neuro-critical care at Harvard, he was appointed the first neurology trained neuro-intensivist at the University of Maryland and R Adams Cowley Shock Trauma Center. At Yale, he is the founding Chief of the Division of Neurocritical Care & Emergency Neurology and Associate Chair for Clinical Research for the Department of Neurology. His interests are in the advancement of therapies for devastating acute neurological syndromes, especially those complicated by brain ischemia, swelling and hemorrhage. He is a nationally recognized clinical and translational scientist and has directed several multicenter studies. In pioneering the development of new strategies to treat brain swelling, his work has changed the fundamental approach to brain injury in the ICU and spurned the creation of new technologies in drug delivery and neuroimaging. His research group uses clinical trials as a platform for discovery, which includes novel imaging and serum based biomarkers for the neuro-ICU. In recent years, this platform has expanded to trials of prevention and recovery in brain injury. His team at Yale has served as a national model for academic critical care neurology units. He is currently the principal investigator for two NIH U24 Neuroscience Networks, NeuroNEXT and StrokeNet and three additional RO1/UO1 awards from the NIH. Dr. Sheth has served as PI or co-PI for 8 multicenter clinical trials in stroke, as well as chair for clinical endpoint and data safety monitoring committees for several pivotal studies. He is the winner of the prestigious Robert Siekert Award from the American Heart Association (AHA), the Derek Denny Brown Award from the American Neurological Association, and member of the American Society of Clinical Investigation (ASCI). His research has been funded by the NIH, American Academy of Neurology, AHA, and the US Army. Dr. Sheth is the author of over 200 publications and has served on study sections for the NIH, AHA, FDA and NASA. He is an Associate Editor at Neurology and on the Critical Care Section Editor for Stroke. His work has been showcased in The Washington Post, Wall Street Journal, NPR and CNN. Finally, Dr. Sheth has formed exciting partnerships with entrepreneurs, pharmaceutical companies, and medical device start-ups to bring forward highly innovative solutions. These efforts have resulted in extensive knowledge of FDA pathways, development of phase I-III drug programs, and implementation of new technology into the clinical workspace. His highly collaborative work is dedicated to the improved understanding of neurological disease in the critically ill. Dr. Sheth is committed to the care of his patients with acute brain injury.